ATE318835T1 - Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile - Google Patents

Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile

Info

Publication number
ATE318835T1
ATE318835T1 AT00936023T AT00936023T ATE318835T1 AT E318835 T1 ATE318835 T1 AT E318835T1 AT 00936023 T AT00936023 T AT 00936023T AT 00936023 T AT00936023 T AT 00936023T AT E318835 T1 ATE318835 T1 AT E318835T1
Authority
AT
Austria
Prior art keywords
peptide
terminus
peptidase activity
amino acid
protection
Prior art date
Application number
AT00936023T
Other languages
German (de)
English (en)
Inventor
Dominique P Bridon
Alan M Ezrin
Peter G Milner
Darren L Holmes
Karen Thibaudeau
Original Assignee
Conjuchem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Inc filed Critical Conjuchem Inc
Application granted granted Critical
Publication of ATE318835T1 publication Critical patent/ATE318835T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00936023T 1999-05-17 2000-05-17 Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile ATE318835T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US15340699P 1999-09-10 1999-09-10
US15978399P 1999-10-15 1999-10-15

Publications (1)

Publication Number Publication Date
ATE318835T1 true ATE318835T1 (de) 2006-03-15

Family

ID=27384581

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00936023T ATE318835T1 (de) 1999-05-17 2000-05-17 Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile

Country Status (11)

Country Link
EP (5) EP1105409B1 (enExample)
JP (6) JP4217004B2 (enExample)
AT (1) ATE318835T1 (enExample)
AU (1) AU765753B2 (enExample)
CA (4) CA2623458A1 (enExample)
DE (1) DE60026300T2 (enExample)
DK (1) DK1105409T3 (enExample)
ES (1) ES2257298T3 (enExample)
PT (1) PT1105409E (enExample)
SI (1) SI1105409T1 (enExample)
WO (1) WO2000069900A2 (enExample)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DK1180121T3 (da) 1999-05-17 2004-03-01 Conjuchem Inc Langtidsvirkende insulinotrope peptider
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
WO2004011498A2 (en) * 2002-07-31 2004-02-05 Conjuchem Inc. Long lasting natriuretic peptide derivatives
AU2002239414A1 (en) * 2000-11-02 2002-05-27 Bristol-Myers Squibb Company Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
BR0206919A (pt) 2001-02-02 2004-07-06 Conjuchem Inc Derivados de fator de liberação de hormÈnio de crescimento de longa duração
US7112567B2 (en) 2001-02-16 2006-09-26 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
EP1573024A4 (en) 2001-04-10 2007-08-29 Agensys Inc NUCLEIC ACIDS AND SUITABLE PROTEINS SUITABLE FOR THE TREATMENT AND EVIDENCE OF VARIOUS CANCER DISEASES
EP1381627B8 (en) * 2001-04-18 2011-01-12 The Open University Polypeptides derived from amyloid precursor peptide (app) and their uses
US7491702B2 (en) 2001-04-18 2009-02-17 The Open University Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same
WO2002092781A2 (en) * 2001-05-17 2002-11-21 Ceremedix, Inc. Peptide compounds for counteracting reactive oxygen species and free radicals
US7691639B2 (en) 2001-05-31 2010-04-06 Adlyfe, Inc. Misfolded protein sensor method
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
ES2242860T3 (es) 2001-05-31 2005-11-16 Conjuchem, Inc. Inhibidores peptidicos de fusion de larga vida contra infecciones por vih.
EP1435999B1 (en) * 2001-10-18 2012-07-18 Zlatko Ademovic Combination of two bioactive regions of pro-opiomelanocortin hormone
US6822073B2 (en) * 2001-12-20 2004-11-23 Kimberly-Clark Worldwide, Inc. Modular peptide-based reagent
CN1753909A (zh) * 2002-03-19 2006-03-29 株式会社康福来 肽,含有该肽的药物组合物和用于治疗癌症的药物组合物
JP2004008027A (ja) * 2002-06-04 2004-01-15 Japan Science & Technology Corp ｃＡＭＰの産生活性を有する新規ペプチド
WO2004011595A2 (fr) * 2002-07-26 2004-02-05 Institut Pasteur Vecteurs destines au transfert de molecules d'interet dans des cellules cibles
AU2003275116A1 (en) * 2002-09-24 2004-04-19 Frontier Biotechnologies Co., Ltd Peptide derivative fusion inhibitors of hiv infection
US7378495B2 (en) * 2002-10-21 2008-05-27 Pevion Biotech, Ltd. PTH-rP related peptide cancer therapeutics
AU2003290563A1 (en) * 2002-10-31 2004-05-25 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
EP1575511A4 (en) * 2002-11-07 2006-06-28 Us Gov Health & Human Serv NEW TARGET FOR ANGIOGENESIS AND ANTI-ANGIOGENESIS THERAPY
DE60331584D1 (de) * 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
AU2003292685A1 (en) * 2003-01-10 2004-08-10 Niigata Tlo Corporation Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene theraphy
AU2003210714A1 (en) * 2003-01-29 2004-08-30 Advanced Research And Technology Institute, Inc. Immunoregulating compounds and an associated method
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
JP2007523844A (ja) * 2003-04-25 2007-08-23 ジェノバ・リミテッド 心臓血管障害において減少する分泌ポリペプチド種
AU2004261319B2 (en) * 2003-07-25 2010-12-23 Conjuchem Biotechnologies Inc. Long lasting insulin derivatives and methods thereof
WO2005077094A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
WO2005090399A1 (ja) * 2004-03-24 2005-09-29 Gifu International Institute Of Biotechnology 各種細胞の増殖・分化を認識する抗体、その抗体を用いた増殖・分化の評価方法
JP5095391B2 (ja) * 2004-04-20 2012-12-12 スフィンゴテック・ゲーエムベーハー 医療診断におけるタキキニンの前駆体および／またはその断片の使用
DE602005027461D1 (de) 2004-04-21 2011-05-26 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
AU2005235634B2 (en) 2004-04-23 2011-10-20 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
ATE502305T1 (de) * 2004-05-13 2011-04-15 Brahms Gmbh Verwendung von vorstufen von enkephalinen und/oder deren fragmenten in der medizinischen diagnostik
AU2012202855B2 (en) * 2004-09-03 2015-02-26 Philipps-Universitat Marburg GLP-1 and exendin related invention
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
EP1814575A4 (en) 2004-11-24 2010-07-07 Neopro Labs Llc METHOD AND COMPOSITIONS FOR TREATING SUFFERING
JP4720175B2 (ja) * 2004-12-15 2011-07-13 富士ゼロックス株式会社 マレイミジル基含有材料およびその製造方法
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
US8372593B2 (en) 2005-02-15 2013-02-12 Adlyfe, Inc. Method for detecting misfolded proteins and prions
WO2006108686A2 (en) * 2005-04-14 2006-10-19 Aic Bnp agonists
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
WO2006121869A2 (en) * 2005-05-05 2006-11-16 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating mood and anxiety disorders
WO2007049940A1 (en) * 2005-10-27 2007-05-03 Peptron Co., Ltd Bioactive substance-blood protein conjugate and stabilization of a bioactive substance using the same
CA2647835A1 (en) 2006-03-28 2007-10-04 Neopro Labs, Llc Methods and compositions for treating conditions
US7982018B2 (en) 2006-10-16 2011-07-19 Conjuchem, Llc Modified corticotropin releasing factor peptides and uses thereof
WO2008052043A2 (en) * 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
US7910102B2 (en) 2006-10-25 2011-03-22 Amgen Inc. Methods of using conjugated toxin peptide therapeutic agents
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
EP2152725A1 (en) 2007-05-17 2010-02-17 Neopro Labs, LLC Crystalline and amorphous forms of peptide
JP5591691B2 (ja) 2007-05-22 2014-09-17 アムジエン・インコーポレーテツド 生物活性を有する融合タンパク質を作製するための組成物及び方法
WO2009023125A1 (en) * 2007-08-14 2009-02-19 The Board Of Trustees Of The Leland Stanford Junior University Neuronostatin and its uses
CA2699169A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic uses of intermedin 47 and 53 peptides
RU2010114059A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение фибронектинового фрагмента (196-203) в качестве терапевтического средства
EP2197469A2 (en) * 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Use of nf-kappab inhibitor sn50 and optionally angiotensin iii as therapeutic agents in the treatment of eg hbv infection
KR20100057063A (ko) * 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도
MX2010008024A (es) 2008-02-01 2010-12-21 Ascendis Pharma As Profarmaco que comprende un enlazador que se puede separar por si mismo.
ES2563553T3 (es) 2008-04-01 2016-03-15 Novo Nordisk A/S Conjugados de insulina-albúmina
WO2009142727A2 (en) * 2008-05-19 2009-11-26 Vasogenix Pharmaceuticals, Inc. Sequence modified calcitonin gene related peptides (cgrp)
CA2751730A1 (en) 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris
MY161842A (en) * 2009-07-29 2017-05-15 Daiichi Sankyo Co Ltd Motilin-like peptide compound having transmucosal absorbability imparted thereto
NZ598021A (en) 2009-07-31 2014-05-30 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
KR101759499B1 (ko) 2009-07-31 2017-07-19 사노피-아벤티스 도이칠란트 게엠베하 지속형 인슐린 조성물
CA2779161A1 (en) 2009-10-28 2011-05-05 University Of Manitoba Yellow pea seed protein-derived peptides
AU2011220878A1 (en) 2010-02-24 2012-08-23 Merck Sharp & Dohme Corp. Method for increasing N-glycosylation site occupancy on therapeutic glycoproteins produced in Pichia pastoris
AU2011231503C1 (en) * 2010-03-26 2016-03-03 Novo Nordisk A/S Novel glucagon analogues
MX355543B (es) 2010-08-13 2018-04-20 Aileron Therapeutics Inc Star Macrociclos peptidomiméticos.
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
CA2849673A1 (en) 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
TWI643868B (zh) 2011-10-18 2018-12-11 艾利倫治療公司 擬肽巨環化合物
SG11201404648PA (en) 2012-02-15 2014-09-26 Aileron Therapeutics Inc Peptidomimetic macrocycles
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
JP2013179884A (ja) * 2012-03-01 2013-09-12 Mitsubishi Rayon Co Ltd メラニンカスケードに関与する成分を評価するための核酸マイクロアレイ及びメラニンカスケードに関与する成分の評価方法
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
PL2986313T3 (pl) 2013-04-18 2019-12-31 Novo Nordisk A/S Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
PT3016671T (pt) * 2013-07-04 2021-12-02 Univ Barcelona Péptidos ativamente transportados e resistentes à protease como transportes bbb e construtos de transporte de carga
AU2015207776B2 (en) * 2014-01-15 2017-06-15 Fyziologicky Ustav Akademie Ved Cr, V.V.I. Lipidated peptides for lowering blood glucose
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
RU2708068C2 (ru) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Лечение судорог с использованием рекомбинантной щелочной фосфатазы
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
ES2740273T3 (es) * 2015-02-22 2020-02-05 Omnix Medical Ltd Péptidos antimicrobianos
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11530243B2 (en) * 2016-02-18 2022-12-20 Veiove Animal Health Inc. Non-cleavable substance P conjugates and methods of use thereof
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436052A4 (en) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. TREATMENT OF MUSCLE WEAKNESS WITH ALKALINE PHOSPHATASES
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
JP6965362B2 (ja) 2017-03-01 2021-11-10 チェンドゥ フイタイ バイオメディスン カンパニー リミテッドChengdu Huitai Biomedicine Co., Ltd. ポリペプチド、ポリペプチド断片及びその誘導体、並びに応用
BR112019020506A2 (pt) 2017-03-31 2020-08-04 Alexion Pharmaceuticals, Inc. métodos para o tratamento de hipofosfatasia (hpp) em adultos e adolescentes
US12297227B2 (en) 2017-06-02 2025-05-13 Mediford Corporation Method for extracting target protein from biological sample and method for analyzing target protein
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
EP3717508A1 (en) 2017-12-01 2020-10-07 The University of Copenhagen Peptide hormone with one or more o-glycans
EP3773684A1 (en) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
WO2019197313A1 (en) 2018-04-09 2019-10-17 Svar Life Science Ab Glucagon Assay
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
EP3906316A4 (en) * 2018-12-31 2022-11-30 United Neuroscience Limited PEPTIDE IMMUNOGENS FOR TARGETING CALCITONINGEN-RELATED PEPTIDE (CGRP) AND FORMULATIONS THEREOF FOR THE PREVENTION AND TREATMENT OF MIGRAINE
KR20220111693A (ko) 2019-12-09 2022-08-09 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제 폴리펩티드 및 이의 이용 방법
IT202000007720A1 (it) * 2020-04-10 2021-10-10 Alessandra Marconi Peptidi e loro usi
JP2023550784A (ja) * 2020-11-25 2023-12-05 プロリンクス エルエルシー Ｃ－ナトリウム利尿ペプチドの徐放性ヒドロゲルコンジュゲート
KR20230145120A (ko) 2021-02-12 2023-10-17 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제 폴리펩타이드 및 이의 사용 방법
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone
GB202215797D0 (en) 2022-10-25 2022-12-07 Solasta Bio Ltd Insect neuropeptide analogues
US12356995B2 (en) 2023-10-23 2025-07-15 Solasta Bio Limited Insect neuropeptides 9
US12281143B1 (en) 2023-10-23 2025-04-22 Solasta Bio Limited Insect neuropeptides 1
US12302908B2 (en) 2023-10-23 2025-05-20 Solasta Bio Limited Insect neuropeptides 4
US12245588B1 (en) 2023-10-23 2025-03-11 Solasta Bio Limited Insect neuropeptides 2
US12279621B1 (en) 2023-10-23 2025-04-22 Solasta Bio Limited Insect neuropeptides 3
US12245596B1 (en) 2023-10-23 2025-03-11 Solasta Bio Limited Insect neuropeptides 8
WO2025196125A1 (en) * 2024-03-19 2025-09-25 Epoqe Pharma Aps N-terminally modified calcitonin gene-related peptide analogues

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
BE795238A (fr) * 1972-02-09 1973-08-09 Schering Ag Derives d'insuline reticules de maniere intramoleculaire, leur procede de preparation et leur utilisation
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
DE3604868A1 (de) * 1986-02-15 1987-08-20 Behringwerke Ag Insulinderivate, verfahren zu ihrer herstellung und ihre verwendung
DD252539A1 (de) * 1986-09-17 1987-12-23 Berlin Chemie Veb Verfahren zur oralen anwendung biologisch aktiver peptide mit verzoegerter wirkung
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
AU666853B2 (en) 1991-04-05 1996-02-29 Genentech Inc. Platelet aggregation inhibitors having high specificity for GP IIbIIIa
CZ281630B6 (cs) 1992-06-12 1996-11-13 Des-Tyr Dynorphin Partnership Analogy des-tyr dynorfinu
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5446128A (en) * 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
WO1996006626A1 (en) 1994-08-26 1996-03-07 Lee Nancy M Analgesic method with dynorphin analogues truncated at the n-terminus
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
EP0981611A1 (en) * 1997-02-05 2000-03-01 1149336 Ontario Inc. Polynucleotides encoding proexendin, and methods and uses thereof
ATE218892T1 (de) * 1997-11-07 2002-06-15 Conjuchem Inc Affinitätsmarkierer für menschliches serum albumin
IL135835A0 (en) * 1997-11-07 2001-05-20 Conjuchem Inc Novel conjugates of opioids and endogenous carriers
IL138214A0 (en) * 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
JP2002512640A (ja) * 1998-03-23 2002-04-23 コンジュケム，インコーポレーテッド 持続性治療薬の局所送達

Also Published As

Publication number Publication date
SI1105409T1 (sl) 2006-06-30
WO2000069900A9 (en) 2002-07-04
EP2100901A1 (en) 2009-09-16
EP1623994A3 (en) 2008-07-16
JP4217004B2 (ja) 2009-01-28
CA2499211A1 (en) 2000-11-23
DE60026300T2 (de) 2006-11-16
WO2000069900A2 (en) 2000-11-23
PT1105409E (pt) 2006-07-31
EP1105409A2 (en) 2001-06-13
EP1623994A2 (en) 2006-02-08
CA2373680A1 (en) 2000-11-23
JP4221392B2 (ja) 2009-02-12
JP2005263807A (ja) 2005-09-29
DK1105409T3 (da) 2006-07-03
JP2005239736A (ja) 2005-09-08
AU5139300A (en) 2000-12-05
WO2000069900A3 (en) 2001-02-15
CA2623458A1 (en) 2000-11-23
JP2003508350A (ja) 2003-03-04
JP2010168384A (ja) 2010-08-05
AU765753B2 (en) 2003-09-25
JP2009079048A (ja) 2009-04-16
DE60026300D1 (de) 2006-04-27
EP1105409B1 (en) 2006-03-01
CA2373680C (en) 2008-07-29
CA2505617A1 (en) 2000-11-23
EP1591453A1 (en) 2005-11-02
JP4219339B2 (ja) 2009-02-04
ES2257298T3 (es) 2006-08-01
EP1598365A1 (en) 2005-11-23
JP2008150384A (ja) 2008-07-03

Similar Documents

Publication Publication Date Title
ATE318835T1 (de) Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile
Mentlein Proline residues in the maturation and degradation of peptide hormones and neuropeptides
WO1996000503B1 (en) Novel peptides
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
EP0994724A4 (en) METHODS AND COMPOSITIONS TO PREVENT THE REPRODUCTION OF HIV-1
EA200100485A1 (ru) Соединение сдлс и способ его измерения
NO974342D0 (no) Trombininhibitorer basert på aminosyresekvensen til hirudin
ATE399177T1 (de) Derivate therapeutischer peptide
ATE297219T1 (de) Antikörper als arzneimittel gegen lymphocytische tumore (ausschliesslich myelome)
ATE165836T1 (de) Peptide als arzneimittel
CA2420350A1 (en) Membrane penetrating peptides and uses thereof
FI20002041A7 (fi) Syklisiä verisuoniin vaikuttavia peptidejä
NZ336116A (en) Diagnostic agent comprising an amino acid or peptide containing at least one 13C or 14C for pancreatic exocrine function
AU703256B2 (en) Bradykinin analogs as selective thrombin inhibitors
EP1452543A3 (en) RGD (ARG-GLY-ASP) coupled to (neuro)peptides
NO964561D0 (no) Tri-, tetra-, penta-, og polypeptider, og bruken av disse som antidepressiv agent
CA2373252A1 (en) Long lasting anti-angiogenic peptides
US4835253A (en) Specific inhibitors of tissue kallikrein
WO1996032134A3 (de) Konjugat aus einem wirkstoff, einem polyether und ggf. einem nicht als körperfremd angesehenen, nativen protein
TW200602353A (en) Modified secretin and method of synthesizing thereof
Berg et al. Formation of desTyr dynorphins 5–17 by a purified cytosolic aminopeptidase of rat brain
Yoshikawa et al. Biologically active peptides derived from food and blood proteins
Su et al. Investigation into the intestinal metabolism of [D-Ala1] peptide T amide: implication for oral drug delivery
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1105409

Country of ref document: EP

EEIH Change in the person of patent owner